Morinda citrifolia enhanced colon cancer cell growth inhibitor

Abstract

The present invention features methods and formulations or compositions for the treatment of colon cancer, and particularly for the inhibition, prevention and/or reduction of cancerous cell growth, as well as the destruction of early stage cancerous cells within the colon region of a mammal, wherein the formulations and compositions comprise an identified amount or concentration of a processed Morinda citrifolia product or an active ingredient there from, as obtained from the Indian Mulberry plant.

1 - 67 . (canceled)  
   
   
       68 . A formulation for decreasing the proliferation of human colon adenocarcinoma cells comprising: 
 a processed  Morinda citrifolia  product present in an amount between about 0.01 and 100 percent by weight of the composition; and    quercetin.    
   
   
       69 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product comprises  Morinda citrifolia  fruit juice.  
   
   
       70 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product comprises  Morinda citrifolia  puree juice.  
   
   
       71 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product comprises  Morinda citrifolia  puree juice concentrate.  
   
   
       72 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product comprises  Morinda citrifolia  fruit juice concentrate.  
   
   
       73 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product comprises  Morinda citrifolia  dietary fiber.  
   
   
       74 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product of said naturaceutical formulation further comprises an active ingredient Quercetin present in an amount between about 0.1 and 10 percent by weight.  
   
   
       75 . The formulation of  claim 68 , wherein said processed  Morinda citrifolia  product is present in an amount between about 0.01 and 100 percent by weight.  
   
   
       76 . The formulation of  claim 74 , wherein said processed  Morinda citrifolia  product further comprises Rutin.  
   
   
       77 . The formulation of  claim 75 , wherein said Rutin is present in an amount between about 0.1 and 10 percent by weight.  
   
   
       78 . The formulation of  claim 68 , wherein said naturaceutical is administered orally.  
   
   
       79 . The formulation of  claim 68 , wherein said naturaceutical is administered transdermally to said infected area.  
   
   
       80 . The formulation of  claim 68 , wherein said naturaceutical is administered intravenously.  
   
   
       81 . The formulation of  claim 68 , wherein said naturaceutical is administered systemically.